Table 2.
Changes in baseline characteristics seen after treatment with carvedilol.
| Before carvedilol (N = 9) |
After carvedilol (N = 9) |
% Change after treatment | P-value | |
|---|---|---|---|---|
| Body weight (kg) | 89.72 ± 7.10 | 90.32 ± 7.39 | 0.6% | 0.43 |
| BMI (Kg/m²) | 29.26 ± 1.76 | 29.48 ± 1.87 | o.8% | 0.39 |
| Systolic BP (mm Hg) | 142.4 ± 5.09 | 136.9 ± 5.80 | -3.7% | 0.38 |
| Diastolic BP (mm Hg) | 71.4 ± 2.59 | 61.3 ± 3.13³ | -14.1% | 0.003 |
| Heart rate (beats/min) | 67.1 ± 2.16 | 60.7 ± 1.74³ | -9.5% | 0.02 |
| Fasting glucose (mmol/L) | 8.61 ± 0.78 | 9.66 ± 1.31 | 12.2% | 0.20 |
| Fasting insulin (μU/L) | 10.20 ± 3.20 | 13.75 ± 8.42 | 34.8% | 0.68 |
| Hb A1c (%) | 7.6 ± 0.59 | 7.66 ± 0.76 | 0.8% | 0.95 |
| Total Cholesterol (mmol/L) | 4.12 ± 0.28 | 4.48 ± 0.35 | 8.7% | 0.06 |
| LDL (mmol/L) | 2.29 ± 0.31 | 2.5 ± 0.30 | 9.2% | 0.10 |
| HDL (mmol/L) | 1.19 ± 0.06 | 1.24 ± 0.09 | 4.2% | 0.37 |
| TG (mmol/L) | 1.41 ± 0.27 | 1.57 ± 0.28 | 11.3% | 0.38 |
| CRP (mmol/L) | 3.00 ± 0.44 | 2.89 ± 0.26 | -3.7% | 0.68 |
T2DM: Patients with Type 2 Diabetes; M/F: Male/Female; ACE inhibitors: Angiotensin Converting Enzyme inhibitors; AT2B: Angiotensin 2 Blockers; BMI: Body Mass Index, BP: Blood Pressure; Hb A1c: Glycosylated Hemoglobin A1c; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; TG: TriGlyceride; CRP: C-Reactive Protein.